ClinicaliQ Trial Snapshot
- Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers — Recruiting • Phase I • Gastroenterology • NCT07672574.
- Study tracking how the body absorbs, processes and eliminates a single dose of ontunisertib using radioactive labelling in healthy men.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is an open, two-part study in healthy male volunteers, aged 30-65 years. This trial aims to understand how the human body absorbs, distributes, metabolizes and eliminates ontunisertib after a single oral dose of radiolabelled test medicine ([14C]ontunisertib) and determine the routes and rates of elimination of the test medicine. Conditions: Fibrostenotic Crohn's Disease Interventions: Ontunisertib, [14C]ontunisertib, [14C]ontunisertib Lead Sponsor: Agomab Spain S.L.U. Planned Enrollment: 8 participants